Debra Stephanie Barker
Director/Board Member presso BERGENBIO ASA
Patrimonio netto: 79 311 $ in data 29/02/2024
Profilo
Debra Stephanie Barker is currently serving as a Non-Executive Director at CureVac SE, Destiny Pharma Plc, BerGenBio ASA, Arix Bioscience Plc, Hutman Diagnostics AG, Arix Bioscience, and CureVac NV.
She previously worked as the Global Head-Medical Affairs at Novartis AG and as the Chief Medical & Development Officer at Spexis Ltd.
Dr. Barker holds a graduate degree from King's College London and a doctorate degree from Queens' College Cambridge.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ARIX BIOSCIENCE PLC
0.02% | 03/05/2023 | 26 000 ( 0.02% ) | 46 828 $ | 29/02/2024 |
DESTINY PHARMA PLC
0.09% | 25/05/2023 | 88 461 ( 0.09% ) | 28 496 $ | 31/03/2024 |
CUREVAC N.V.
0.00% | 31/03/2023 | 1 316 ( 0.00% ) | 3 987 $ | 31/03/2024 |
Posizioni attive di Debra Stephanie Barker
| Società | Posizione | Inizio |
|---|---|---|
| BERGENBIO ASA | Director/Board Member | 13/03/2019 |
| DESTINY PHARMA PLC | Director/Board Member | 01/01/2020 |
| CUREVAC N.V. | Director/Board Member | 22/06/2022 |
| ARIX BIOSCIENCE PLC | Director/Board Member | 10/08/2022 |
Hutman Diagnostics AG
 Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Director/Board Member | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Director/Board Member | - |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Director/Board Member | 01/08/2022 |
Precedenti posizioni note di Debra Stephanie Barker
| Società | Posizione | Fine |
|---|---|---|
| SPEXIS AG | Chief Tech/Sci/R&D Officer | 31/12/2018 |
| NOVARTIS AG | Corporate Officer/Principal | - |
Formazione di Debra Stephanie Barker
| King's College London | Graduate Degree |
| Queens' College Cambridge | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 6 |
|---|---|
| NOVARTIS AG | Health Technology |
| SPEXIS AG | Health Technology |
| DESTINY PHARMA PLC | Health Technology |
| BERGENBIO ASA | Health Technology |
| ARIX BIOSCIENCE PLC | Finance |
| CUREVAC N.V. | Health Technology |
| Aziende private | 3 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Health Technology |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Finance |
- Borsa valori
- Insiders
- Debra Stephanie Barker
